Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF vs rhG-CSF for Neutropenia in Cervical or Endometrial Cancer
NCT07865650Active, not recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of pegfilgrastim in neutropenia (2 arms), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoints: Incidence of Grade 3 or Higher Neutropenia During Radiotherapy and Incidence of Grade 3 or Higher Neutropenia During the Post-Radiotherapy Observation Period at 6 months. Started Sep 2026; status: active, not recruiting.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT07865650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07865650.